Silo Pharma, Inc. announced that it has entered into an exclusive global license agreement to further develop, manufacture, and commercialize its Alzheimer's drug SPC-14. Silo intends to utilize the FDA's streamlined 505(b)(2) pathway for SPC-14, which would shorten clinical timelines and reduce drug development costs. Silo Pharma recently announced a similar exclusive license agreement for its lead drug candidate, SPC-15, an intranasal treatment for stress-induced affective disorders and PTSD.